Isofol Medical AB (publ) reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was SEK 2.91 million compared to SEK 5.15 million a year ago. Revenue was SEK 2.91 million compared to SEK 5.15 million a year ago. Net loss was SEK 32.51 million compared to SEK 51.03 million a year ago. Basic loss per share from continuing operations was SEK 0.2 compared to SEK 0.32 a year ago. Diluted loss per share from continuing operations was SEK 0.2 compared to SEK 0.32 a year ago.
For the nine months, sales was SEK 10.94 million compared to SEK 17.7 million a year ago. Revenue was SEK 10.94 million compared to SEK 17.7 million a year ago. Net loss was SEK 134.42 million compared to SEK 139.08 million a year ago. Basic loss per share from continuing operations was SEK 0.83 compared to SEK 1.22 a year ago. Diluted loss per share from continuing operations was SEK 0.83 compared to SEK 1.22 a year ago.